Cormedix Inc (CRMD)
4.49
-0.23
(-4.87%)
USD |
NASDAQ |
Jun 17, 16:00
4.49
0.00 (0.00%)
After-Hours: 20:00
Cormedix Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2022 | 0.0297M |
| September 30, 2022 | 0.0068M |
| June 30, 2022 | 0.0213M |
| March 31, 2022 | 0.0076M |
| December 31, 2021 | 0.0564M |
| September 30, 2021 | 0.0381M |
| June 30, 2021 | 0.0082M |
| March 31, 2021 | 0.0883M |
| December 31, 2020 | 0.0557M |
| September 30, 2020 | 0.093M |
| June 30, 2020 | 0.0164M |
| March 31, 2020 | 0.0741M |
| December 31, 2019 | 0.0248M |
| September 30, 2019 | 0.0595M |
| June 30, 2019 | 0.0353M |
| March 31, 2019 | 0.1637M |
| December 31, 2018 | 0.0265M |
| September 30, 2018 | 0.3725M |
| June 30, 2018 | 0.0076M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.0232M |
| December 31, 2017 | 0.0925M |
| September 30, 2017 | 0.0611M |
| June 30, 2017 | 0.1362M |
| March 31, 2017 | 0.0396M |
| December 31, 2016 | 0.1217M |
| September 30, 2016 | 0.0445M |
| June 30, 2016 | 0.0165M |
| March 31, 2016 | 0.0414M |
| December 31, 2015 | 0.0229M |
| September 30, 2015 | 0.0359M |
| June 30, 2015 | 0.12M |
| March 31, 2015 | 0.0313M |
| December 31, 2014 | 0.0849M |
| September 30, 2014 | 0.0524M |
| June 30, 2014 | 0.0397M |
| March 31, 2014 | 0.0122M |
| December 31, 2013 | 0.002M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0068M
Minimum
Sep 2022
0.093M
Maximum
Sep 2020
0.041M
Average
0.0353M
Median
Jun 2019
Revenue (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 205.83M |
| Cassava Sciences Inc | -- |
| Vertex Pharmaceuticals Inc | 2.691B |
| Regulus Therapeutics Inc | -- |
| Oragenics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.47M |
| Total Expenses (Quarterly) | 16.70M |
| EPS Diluted (Quarterly) | -0.25 |
| Enterprise Value | 188.22M |
| Earnings Yield | -20.71% |
| Normalized Earnings Yield | -16.50 |